Basal cytokeratin expression in relation to biological factors in breast cancer.

[1]  H. Yamashiro,et al.  Update of evidence in chemotherapy for breast cancer , 2008, International Journal of Clinical Oncology.

[2]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[3]  Sung-Bae Kim,et al.  Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. , 2006, Human pathology.

[4]  Andreas Makris,et al.  Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer , 2006, Breast Cancer Research.

[5]  C. Caldas,et al.  Molecular classification and molecular forecasting of breast cancer: ready for clinical application? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Ball,et al.  High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.

[7]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[8]  A. Makris,et al.  Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer , 2004, British Journal of Cancer.

[9]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[10]  I. Ellis,et al.  Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.

[11]  L. Bégin,et al.  The Prognostic Implication of the Basal-Like (Cyclin Ehigh/p27low/p53+/Glomeruloid-Microvascular-Proliferation+) Phenotype of BRCA1-Related Breast Cancer , 2004, Cancer Research.

[12]  T. Powles,et al.  Studies of the Potential Utility of Ki67 as a Predictive Molecular Marker of Clinical Response in Primary Breast Cancer , 2003, Breast Cancer Research and Treatment.

[13]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Foekens,et al.  RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  Martin Eisenacher,et al.  Cytogenetic Alterations and Cytokeratin Expression Patterns in Breast Cancer: Integrating a New Model of Breast Differentiation into Cytogenetic Pathways of Breast Carcinogenesis , 2002, Laboratory Investigation.

[16]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Schneider,et al.  Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy , 2001, Breast Cancer Research.

[18]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[19]  J. Nesland,et al.  The prognostic value of p53 and c‐erb b‐2 immunostaining is overrated for patients with lymph node negative breast carcinoma , 2000, Cancer.

[20]  D. Hipfner,et al.  Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  R. Moll,et al.  Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas , 1998, Virchows Archiv.

[22]  H. Kim,et al.  Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  Philip Smith,et al.  p53 immunohistochemical staining and survival after adjuvant chemotherapy for breast cancer , 1997, International journal of cancer.

[24]  Y. Maehara,et al.  Expression of multidrug‐resistance‐associated protein (MRP) and chemosensitivity in human gastric cancer , 1996, International journal of cancer.

[25]  A. Harris,et al.  Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  T. Aikou,et al.  Expression of the multidrug‐resistance‐associated protein (MRP) gene in human colorectal, gastric and non‐small‐cell lung carcinomas , 1996, International journal of cancer.

[27]  S. Hilsenbeck,et al.  Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  Y. Oshika,et al.  Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. , 1995, British Journal of Cancer.

[29]  I. Ellis,et al.  Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. , 1995, British Journal of Cancer.

[30]  J. L. Biedler.  Genetic aspects of multidrug resistance , 1992, Cancer.

[31]  J. Schulte‐Mönting,et al.  Ki‐67 immunostaining in human breast tumors and its relationship to prognosis , 1991, Cancer.

[32]  Tetsu Yamamoto,et al.  Histopathological assessment of multidrug resistance in gastric cancer: Expression of P-glycoprotein, multidrug resistance-associated protein, and lung-resistance protein , 2006, Surgery Today.

[33]  T. Powles,et al.  Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study , 2004, Breast Cancer Research and Treatment.

[34]  W. El-Deiry,et al.  Regulation of p53 downstream genes. , 1998, Seminars in cancer biology.

[35]  P. Sedlaczek,et al.  Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement. , 1998, Anticancer research.

[36]  G. Woods,et al.  P‐glycoprotein mediated multidrug resistance and its implications for pathology , 1997, Pathology.

[37]  I. Pastan,et al.  Expression of a multidrug-resistance gene in human tumors and tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Tibshirani,et al.  Copyright © American Society for Investigative Pathology Short Communication Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome , 2022 .